Compare ARCO & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCO | GLPG |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | Uruguay | Belgium |
| Employees | N/A | 704 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2011 | N/A |
| Metric | ARCO | GLPG |
|---|---|---|
| Price | $8.04 | $29.16 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $8.60 | ★ $36.50 |
| AVG Volume (30 Days) | ★ 1.2M | 139.0K |
| Earning Date | 03-19-2026 | 04-22-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.64 | N/A |
| Revenue Next Year | $6.59 | N/A |
| P/E Ratio | $7.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.51 | $22.59 |
| 52 Week High | $8.98 | $37.78 |
| Indicator | ARCO | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 47.84 | 30.94 |
| Support Level | $7.99 | $28.78 |
| Resistance Level | $8.06 | $29.28 |
| Average True Range (ATR) | 0.26 | 0.79 |
| MACD | 0.03 | -0.33 |
| Stochastic Oscillator | 56.02 | 1.05 |
Arcos Dorados Holdings Inc operates McDonald's branded restaurants in various countries and territories in Latin America and the Caribbean. The Company manages its business as distinct geographic segments and its operations are divided into three geographic divisions, as follows: Brazil, the North Latin American division, or NOLAD, which is comprised of Costa Rica, Mexico, Panama, Puerto Rico, Martinique, Guadeloupe, French Guiana and the U.S. Virgin Islands of St. Croix and St. Thomas and the South Latin American division, or SLAD, which is comprised of Argentina, Chile, Ecuador, Peru, Uruguay, Colombia, Venezuela, Trinidad and Tobago, Aruba and Curacao. Their menu includes hamburgers, McNuggets, salad, sandwiches, French fries, and others.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.